What this study is
SURGE aims to increase representation in clinical trial enrollment by addressing barriers to genomic testing, which is increasingly needed to assess precision clinical trial eligibility and access standard precision therapies. The study is an interventional pilot meant primarily to assess the feasibility of the intervention. The intervention is comprised of a patient navigator, text message questionnaire, and informational video.
What's being tested
- SURGE
Intervention · BEHAVIORAL
Video with or without person to person guidance to support decision making around genetic testing
Study details
- Sponsor
- Nadine Jackson, MD, MPH
- Conditions
- Gastrointestinal Cancer · Hematologic Cancer · Thoracic Cancer
- Enrolling
- 210 people
- Starts
- 2023-04-03
- Est. completion
- 2028-07-30
- Design
- Open-label, randomized, parallel groups
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years and overSex ALLHealthy volunteers Not acceptedYou may qualify if
- Adult (age 18 years or older)
- Scheduled for a new patient consultation
- Suspected or confirmed advanced malignancy (requiring active treatment)
- DFCI patient at Longwood/Chestnut Hill, DFCI satellite at BMC-Brighton (formerly St. Elizabeth's Medical Center), DFCI satellite at Foxborough, or DFCI satellite at Merrimack Valley
You can't join if
- Malignancy or former malignancy that requires only surveillance
- Not continuing care at a participating DFCI site
- Speaks a language other than English, Spanish, Haitian Creole, Russian, Portuguese, Arabic, or Traditional Chinese
- Unable to provide consent
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (3)
3 openDana Farber Cancer Institute
Boston, Massachusetts, United States
- Nadine J. McCleary, MD, MPH · Contact(617) 632-6729nj_mccleary@dfci.harvard.edu
- Nadine J. McCleary, MD, MPH · Principal investigator
RecruitingDana-Farber Cancer Institute at St. Elizabeth's Medical Center
Brighton, Massachusetts, United States
- Olga Kozyreva, MD · Contactolga_kozyreva@dfci.harvard.edu
- Olga Kozyreva, MD · Principal investigator
RecruitingDana-Farber Cancer Instiute - Merrimack Valley
Methuen, Massachusetts, United States
- Pedro Sanz-Altamira, MD · Contactpedro_sanz-altamira@dfci.harvard.edu
- Pedro Sanz-Altamira, MD · Principal investigator
Not yet recruiting
Study team
Sponsor
Nadine Jackson, MD, MPH
Study ID 21-709
Principal investigator
Nadine A Jackson, MD MPH
Dana-Farber Cancer Institute
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.